Nextstellis Kit
NDC Package 51862-258-01
Package Information
Nextstellis (drospirenone and estetrol) kits is nEXTSTELLIS is indicated for use by females of reproductive potential to prevent pregnancy. This formulation utilizes a kit delivery system. Marketed by Mayne Pharma, this product is identified by NDC 51862-258 and is authorized under FDA application NDA214154.
Identification & Billing
- RxCUI: 2539032 - {24 (drospirenone 3 MG / estetrol 14.2 MG Oral Tablet) / 4 (inert ingredients 1 MG Oral Tablet) } Pack [Nextstellis 28 Day]
- RxCUI: 2539032 - Nextstellis 28 Day Pack
- RxCUI: 2539033 - drospirenone 3 MG / estetrol 14.2 MG Oral Tablet
- RxCUI: 2539036 - {24 (drospirenone 3 MG / estetrol 14.2 MG Oral Tablet) / 4 (inert ingredients 1 MG Oral Tablet) } Pack
- RxCUI: 2539036 - drospiren-estetrol 3-14.2 MG (24) Oral Tablet / Inert 1 MG (4) Oral Tablet 28 Day Pack
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 51862 - Mayne Pharma
- 51862-258 - Nextstellis
- 51862-258-01 - 1 BLISTER PACK in 1 CARTON / 1 KIT in 1 BLISTER PACK * 24 TABLET, FILM COATED in 1 BLISTER PACK (51862-259-24) * 4 TABLET, FILM COATED in 1 BLISTER PACK (51862-261-04)
- 51862-258 - Nextstellis
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Other Available Packages
The following commercial packages are registered under the same Product NDC (51862-258). Click a package code to view its specific billing and regulatory data.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 51862-258-01 identifies a specific commercial package of 1 blister pack in 1 carton / 1 kit in 1 blister pack * 24 tablet, film coated in 1 blister pack (51862-259-24) * 4 tablet, film coated in 1 blister pack (51862-261-04) of Nextstellis, a human prescription drug labeled by Mayne Pharma. This kit is formulated for use and contains as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Mayne Pharma on April 16, 2021. The current certification is valid through December 31, 2026.
How is this Mayne Pharma product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 51862025801. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.
